<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079233</url>
  </required_header>
  <id_info>
    <org_study_id>CTST-16</org_study_id>
    <nct_id>NCT02079233</nct_id>
  </id_info>
  <brief_title>Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers</brief_title>
  <official_title>Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorbent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorbent Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the effect of four different dosing regimens of CLP in normal
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fecal sodium content</measure>
    <time_frame>Baseline (Days 3-6) vs. Treatment (Days 10-13)</time_frame>
    <description>The primary endpoint was sodium removal from the stool compared between the Baseline period and the Treatment Period.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CLP 15 g QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLP 7.5 g BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLP 5 g TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLP 3.75 g QID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cross-Linked Polyelectrolyte (CLP)</intervention_name>
    <description>CLP was administered orally, in capsules, for 7 consecutive days.</description>
    <arm_group_label>CLP 15 g QD</arm_group_label>
    <arm_group_label>CLP 7.5 g BID</arm_group_label>
    <arm_group_label>CLP 5 g TID</arm_group_label>
    <arm_group_label>CLP 3.75 g QID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer is â‰¥ 18 years of age with BMI of 18-32

          -  Females could not be pregnant or breast feeding and had to be using birth control

          -  Must have regular bowel habits, typically producing at least 1 daily bowel movement

        Exclusion Criteria:

          -  Screening 12-lead ECG demonstrating QTc interval &gt;430 msec for males and &gt;450 msec for
             females, or any cardiac rhythm disorder considered by the Investigator to be
             clinically relevant

          -  History or presence of gastrointestinal conditions

          -  Positive drug screen for substances of abuse

          -  Positive results for HIV, hepatitis B, or hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanthini A. Daniel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jasper Clinic, Inc.</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Basic Science</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Efficacy of CLP</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

